Agents for refractory/relapsed acute lymphocytic leukemia in adults

作者：Qian, L. -R.^*; Fu, W.; Shen, J. -L.

来源：European Review for Medical and Pharmacological Sciences, 2014, 18(17): 2465-2474.

• Acute lymphocytic leukemia
• Refractory
• Relapsed
• Treatment

Although treatment results for adult acute lymphoblastic leukemia (ALL) have improved considerably in the past decades, treating adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) is still difficult. Adults with refractory/relapsed acute lymphocytic leukemia (ALL) processed to death rapidly associated with chemotherapy resistance, high mortality by reinduction, etc. Only 20% to 30% of those patients acquired complete remission (CR). Those patients are always of short duration unless an allogeneic stem cell transplant is feasible. Median survival is only ranging from 2 to 12 months. Therapeutic strategy on relapsed/refractory acute lymphocytic leukemia (ALL) is always a major therapeutic challenge bothering hematological researchers. Novel agents and unique therapeutic strategies have been developed in recent years. This review focuses on major clinical advances in the agents for refractory/relapsed ALL.

• 出版日期2014-9
• 单位中国人民解放军海军总医院